Tylenol-maker Kenvue shares bounce, Trump claims face pushback

Core Insights - Kenvue, the maker of Tylenol, experienced a rise in stock prices during European trading despite controversial comments made by U.S. President Donald Trump linking its pain medication to autism risk during pregnancy [1] Company Summary - Kenvue's stock performance indicates resilience in the face of negative publicity, suggesting potential investor confidence in the company's long-term prospects [1] Industry Summary - The incident highlights ongoing concerns regarding the safety of over-the-counter medications during pregnancy, which may impact consumer perception and regulatory scrutiny in the pharmaceutical industry [1]